Management of the Disease *Utilize the required Clinical Practice Guideline (CPG) to support your treatment recommendations. 1.Identify two (2) "Evidence A"recommended medication classesfor the treatment of this condition and provide an example (drug name) for each.

The goal of "Evidence A" recommended pharmacological treatment regimen should include medications with adequate efficacy that will reduce cardiorenal risk and be seamless to maintain. One of the drug classifications is glucagon-like peptide 1 (GLP-1), either oral form or injection. Another drug classification is sodium-glucose co-transporter-2 (SGLT2inhibitors) (ElSayed et al., 2023; Practice guidelines resources, 2023) The GLP-1 agonist drug example is Ozempic (semaglutide) and the SGLTs inhibitors drug example Empagliflozin (Jardiance w/metformin) (ElSayed et al., 2023;Practice guidelines resources, 2023). 2.Describe the mechanism of actionfor each of the medication classes identified above. The mechanism of action for the GLP-1 agonist drug Ozempic (semaglutide) works by binding to theGLP-1 receptors in the pancreas and then stimulating the pancreas to releaseinsulin,reduced glucagon release-responses which lowers blood sugar. These effects can help manage blood sugar and decrease blood sugar spikes by inhibiting gastric motility and secretion (Practice guidelines resources, 2023).  SGLT-2 inhibitor drugs are administered in oral form and its mechanism of action depends on the individual's kidney function. This drug class reduces the amount of glucose being absorbed in the kidneys by preventing the action of SGLT2 cotransporters in the kidney. Further explanation, SGLT-2 reduces renal tubularglucose reabsorption,which produces a reduction in blood glucose without stimulatingthe pancreas to produce and release insulin (ElSayed et al., 2023;Practice guidelines resources, 2023) 3.Identify two (2) "Evidence A" recommended non-pharmacological treatmentoptions for this patient